Clinical trials: No Evidence of Disease
Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
This randomized phase I trial studies the side effects and the best dose of letrozole in preventing breast cancer in healthy postmenopausal women at high risk for breast cancer.
- Trial name
- NCT01077453
- Testing
- letrozole, quality-of-life assessment, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
No Evidence of Disease
Study of 9cUAB30 in Healthy Participants
This research study is looking at 9cUAB30 in healthy participants. Studying samples of blood and urine from healthy participants may help doctors learn more about how 9cUAB30 is used by the body.
- Trial name
- NCT00896974
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Retinoid 9cUAB30
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
This is a prospective, double-blind placebo-controlled, multicenter, randomized phase II trial testing the adjuvant immunotherapy with Nivolumab plus Ipilimumab Placebo or Nivolumab plus Ipilimumab versus Double Placebo Control…
- Trial name
- NCT02523313
- Testing
- Nivolumab + Ipilimumab
- Where
- 20 sites in Germany
- Volunteers
- 167 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with kidney cancer that has spread to other parts of the body and have no evidence of disease after surgery.
- Trial name
- NCT01575548
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride
- Where
- 579 sites in United States
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Cytomegalovirus Infection, Healthy, no Evidence of Disease
Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus
This phase I trial studies the side effects and the best dose of vaccine therapy in healthy volunteers with or without previous exposure to cytomegalovirus.
- Trial name
- NCT01941056
- Testing
- multi-CMV epitope modified vaccinia Ankara vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Breast Cancer
Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease
This study will evaluate the safety and feasibility of administering a peptide vaccine consisting of twelve different tumor-rejection antigens to patients with high risk (TxN2-3M0) or metastatic breast cancer with no evidence of…
- Trial name
- NCT00674791
- Testing
- OCPM Immunotherapeutic Vaccine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return.
- Conditions
- Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
- Trial name
- NCT05642195
- Testing
- Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
This is an open label, 2-arm, 1-stage, randomized controlled phase II study in patients with AJCC stage IIIB/C \& -IV melanoma. At baseline tumor assessment (using total body FDG-PET/CT), patients should be free from measurable…
- Trial name
- DC-MEL (NCT01676779)
- Testing
- Dendritic cell therapy
- Where
- Belgium
- Volunteers
- 88 people
- Sponsor
- Universitair Ziekenhuis Brussel
Breast Cancer
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease
The purpose of this research study is to learn about the effects of two drugs when they are given together. The names of the drugs are raloxifene and exemestane. Raloxifene is a drug that is related to estrogen.
- Trial name
- NCT00200174
- Testing
- Raloxifene followed by combination therapy, Exemestane followed by combination therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy Stem Cell Donor, No Evidence of Disease
Collection of Bone Marrow From Donors Treated With or Without Filgrastim
This randomized clinical trial is studying the side effects of collection of bone marrow from donors treated with or without filgrastim.
- Trial name
- NCT01149096
- Testing
- Bone Marrow Donation, Filgrastim, Laboratory Biomarker Analysis
- Where
- 22 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Prostate Cancer
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00020254
- Testing
- aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Healthy, no Evidence of Disease
Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Eating a diet high in isoflavones, compounds found in soy foods, may keep cancer from forming.
- Trial name
- NCT00513916
- Testing
- soy isoflavones
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Hawaii Cancer Research Center
HER2/Neu Negative, No Evidence of Disease
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
This phase I trial studies the side effects and best dose of a vaccine therapy in preventing cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast…
- Conditions
- HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer
- Trial name
- WOKVAC (NCT02780401)
- Testing
- Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Healthy, no Evidence of Disease, Obesity
Study of a Smart Growth Community's Effect on Prevention of Obesity in Middle-, Moderately Low- and Low-Income Families
RATIONALE: Overweight and obesity have been associated with multiple types of disease, including cancer. Living in a smart growth community may encourage behaviors that would reduce the risk of obesity.
- Conditions
- Healthy, no Evidence of Disease, Obesity, Weight Changes
- Trial name
- NCT00986011
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, survey administration
- Where
- United States
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Breast Cancer
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00847171
- Testing
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Healthy, no Evidence of Disease
A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants
RATIONALE: Studying samples of blood and urine from healthy participants receiving antioxidant nutritional supplements may help doctors identify changes in biomarkers related to oxidative stress.
- Trial name
- NCT00768118
- Testing
- curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule, electrophoretic mobility shift assay, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Breast Carcinoma, Ductal Breast Carcinoma In Situ
Oxybutynin Chloride in Managing Hot Flashes
This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy.
- Conditions
- Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ
- Trial name
- NCT02961790
- Testing
- Oxybutynin Chloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Academic and Community Cancer Research United
MS (Multiple Sclerosis), Multiple Sclerosis (MS) - Relapsing-remitting
Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis
This observational study investigates if switching from MabThera® to Rixathon® is associated with changes in disease activity and/or safety in people with multiple sclerosis (MS).
- Conditions
- MS (Multiple Sclerosis), Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (Relapsing Remitting)
- Trial name
- NCT07235644
- Where
- Sweden
- Volunteers
- 184 people
- Sponsor
- Uppsala University
Temporomandibular Joint and Muscle Disorder
An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)
With the great economic costs and traditionally poor outcomes among chronic temporomandibular joint and muscle disorder (TMJMD) patients, it has become important to treat patients in the acute state, in order to prevent these…
- Trial name
- NCT00952900
- Testing
- Biobehavioral, Active Coping/Attention Intervention
- Where
- United States
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Arlington
Colorectal Cancer
Second Look Laparoscopy in Colorectal Cancer
The purpose of this study is to evaluate whether a second-look laparoscopy, followed by peritonectomy, hyperthermic intraperitoneal chemotherapy (HIPEC) or systemic chemotherapy in case of peritoneal carcinosis, improves the…
- Trial name
- HIPEC (NCT01628211)
- Testing
- Laparoscopy, peritonectomy, Folinic Acid
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute, Naples